Mindray Receives CE Marking Approval for HIV and HBV CLIA Test Kits

Food and Healthcare Press Releases Wednesday October 25, 2017 08:04
SHENZHEN, China--25 Oct--PRNewswire/InfoQuest
Mindray is the first and only Chinese medical device company to have passed the assessment of the European Directive 98/79/EC (IVDD) for List A tests.

Mindray announced it has received CE Marking certificates issued by TUV SUD, a global certification body for medical devices, for its HIV and HBV (HBsAg, Anti-HBs, Anti-HBc, HBeAg, and Anti-HBe) CLIA (Chemiluminescence Immunoassay) test kits. Mindray becomes the first and only Chinese medical device company to receive List A CE Marking for infectious disease tests.

"Infectious disease tests are one of the most complicated and stringent CLIA assays due to complexity of samples and the existence of mutations. Over the last few years Mindray's R&D team has been committed to tackling the difficulties and challenges. Now we have finally obtained CE certifications for these List A assays," Mr. Haitao Huang, Vice President of Mindray Group, said at the CE certification announcement.

"We have applied a number of patented technologies in the infectious disease assays to shorten the window period and reduce the endogenous interference of samples from pregnant women, the elderly, and patients with hepatic or renal diseases," added Mr. Zhaoyang Li, General Manager of Mindray In-Vitro Diagnostics Business Unit. Behind Mindray's high quality products are its globally integrated innovation platform and world-class quality control system. Every year Mindray invests around 10% of its revenues in R&D to drive development of safe and dependable medical applications resulting in solutions that are trusted by customers worldwide and certified with international standards such as FDA and CE Marking.

Mindray 4th-generation HIV assay

The Mindray CL-series HIV assay is a Chemiluminescent Immunoassay for the simultaneous qualitative determination of both HIV p24 antigen prior to seroconversion, and antibodies to HIV-1 (including Group M & O) and HIV-2 in human serum or plasma. This 4th-generation HIV assay shortens the detection window and improves detection sensitivity of early HIV infection. It may be used as an aid in the diagnosis of HIV-1/HIV-2 infection and as a screening test for donated blood.

Mindray:

Mindray is a leading global developer of medical devices and solutions, dedicated to making better healthcare more accessible to humanity. Since its foundation in 1991, Mindray has been exclusively focused on the medical industry in the fields of Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging.   www.mindray.com/en


Latest Press Release

Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows

Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands...

2018 Empire State Building Run-Up Lottery Registration Opens on November 14, 2017

Runners must enter by December 10 for a chance to participate in the 41st Annual Run-Up on Wednesday, February 7, 2018, at 8:00 p.m. Empire State Realty Trust, Inc. (NYSE: ESRT) today announced that lottery registration for the 2018 Empire State...

Alpinion Medical Systems Launches E-CUBE 8, the New Ultrasound Diagnostic System

One of South Korea's global medical device manufacturers, Alpinion Medical Systems introduced its new E-CUBE 8, the latest and last addition to the E-CUBE lineup. The E-CUBE 8 is a smart, reliable product that ensures high performance with outstanding...

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk...

Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from...

Related Topics